euro adhoc: Sartorius AG / Financial Figures/Balance Sheet / Preliminary Figures for Fiscal 2005 (E)

--------------------------------------------------------------------------------
Disclosure announcement transmitted by euro adhoc.
The issuer is responsible for the content of this announcement.
--------------------------------------------------------------------------------

02.02.2006

Group earnings (EBIT) improved by 34.3% / Earnings per share up
from EUR0.89 to EUR1.30 / Sales revenue up 3.6% / Order intake up 7.7% /
Profitable growth expected to be continued in 2006

In fiscal 2005, the Sartorius Group boosted earnings before interest, taxes,
depreciation and amortization (EBITDA) 14.1% from EUR54.8 million to EUR62.5
million. Earnings before interest and taxes (EBIT) reached EUR43.7 million and
were thus 34.3% above the year-earlier figure (EUR32.5 mn). This corresponds to
an EBIT margin of 9.0% (previous year: 7.0%). For the Biotechnology Division,
EBIT was EUR24.3 million (EUR17.5 mn); for the Mechatronics Division, EUR19.4
million (EUR15.0 mn).

As goodwill amortization ceased to be applied (EUR2.4 mn), this had a positive
impact on EBIT. Expenses for derivative financial instruments had a negative
impact in a similar amount on the financial result. Net profit surged 45.1% to
EUR22.1 million (EUR15.2 mn); earnings per share climbed from EUR0.89 to
EUR1.30.

Group sales revenue rose 3.6% (currency adjusted: +3.5%) to EUR484.3 million
(EUR467.6 mn). The Biotechnology Division posted a 4.3% increase in sales
revenue to EUR249.8 million (EUR239.4 mn); the Mechatronics Division, 2.8% to
EUR234.5 million (EUR228.1 mn). Consolidated order intake grew 7.7% (currency
adjusted: +7.7%) to EUR497.0 million (EUR461.6 mn).

The considerably positive net cash flow of EUR33.0 million (EUR36.3 mn) was
primarily used to reduce net debt by EUR18.1 million to EUR60.7 million.

In fiscal 2006, Sartorius is striving to continue profitable growth and, on the
basis of constant currencies, assumes that it will achieve an increase in sales
revenue of over 5%. In addition, the company intends to raise EBIT to approx.
10% of consolidated sales revenue.

The figures stated above are still subject to the auditors' final review. The
final numbers will be published at the annual press conference, which has been
moved up to March 14, 2006.

Further inquiry note:
Andreas Wiederhold
Phone +49.551.308.1668
[email protected]

end of announcement euro adhoc 02.02.2006 20:07:37
--------------------------------------------------------------------------------

emitter: Sartorius AG
Weender Landstr. 94-108
D-37075 Göttingen
phone: +49 (0)551 308 0
FAX: +49 (0)551 308 289
mail: [email protected]
WWW: http://www.sartorius.com
ISIN: DE0007165607, DE0007165631
indexes: CDAX, Prime All Share, Technologie All Share
stockmarkets: official dealing/prime standard: Frankfurter Wertpapierbörse, free
trade: Börse Berlin-Bremen, Hamburger Wertpapierbörse,
Baden-Württembergische Wertpapierbörse, Börse Düsseldorf,
Bayerische Börse, official dealing: Niedersächsische Börse zu
Hannover
sector: Biotechnology
language: English

OTS-ORIGINALTEXT UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS | OTB

print